Sangamo Therapeutics

Sandy Macrae, Ph.D., CEO

Oct. 13 | 2:00pm | AVROBIO Ballroom

Brisbane, CA

(NASDAQ: SGMO)

In-person Presentation

Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance programs into the clinic. Our platforms have yielded multiple clinical-stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality, and supply. Our ability to fund our projects enables us to execute and deliver on our mission.

www.sangamo.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions